贝伐单抗联合伊立替康治疗复发性脑胶质瘤的临床观察  

CLINICAL OBSERVATION OF BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT CEREBRAL GLIOMA

作　　者：贾佳[1] 刘彦芳[1] 于忠和[1] 

机构地区：[1]北京军区总医院肿瘤科,北京市100700

出　　处：《中国煤炭工业医学杂志》2013年第6期923-924,共2页Chinese Journal of Coal Industry Medicine

摘　　要：目的分析探讨贝伐单抗与伊立替康联合治疗复发性脑胶质瘤的近期疗效。方法 14例复发性脑胶质瘤患者应用贝伐单抗联合伊立替康化疗,具体方案:贝伐单抗5mg/kg,d1静滴+伊立替康120mg/m2,d2静滴,观察其临床疗效、不良反应。结果 14例患者中,5例部分缓解(35.7%),7例稳定(50%),2例进展(14.3%),客观有效率为35.7%,疾病控制率为85.7%,随访6个月无进展生存率为71.4%(10/14)。不良反应较轻,患者均可耐受。结论贝伐单抗与伊立替康联合用于复发性脑胶质瘤患者治疗效果较好,不良反应一般可耐受。Objective To evaluate the short- term curative effect of bevacizumab in combination with irino- tecan for recurrent cerebral glioma. Methods Fourteen cases of recurrent cerebral glioma were enrolled in this study. To observe the clinical efficacy and adverse reactions, all the patients received Bevacizumab （5mg/kg,iv,dl） and irinotecan （120mg/m2 ,iv,d2） ,14 days was a cycle. Results All of the 14 cases, there were 5 cases with partial remission （35.7%） , 7 cases with stable disease （50%） and 2 cases with pro- gressive disease （14.3%）. The follow up 6- month progression- free survival rate was 71.4% （10/14）, and all patients could be tolerated with a lighter adverse reaction,Conclusion Bevacizumab in combination with irinotecan is effective in the treatment of recurrent cerebral glioma with a mild side effect.

关 键 词：脑胶质瘤 复发性 贝伐单抗 伊立替康 

分 类 号：R739.41[医药卫生—肿瘤]